RAS Inhibitors Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (ACE Inhibitors (Lisinopril, Enalapril, Ramipril), ARBs (Losartan, Valsartan, Candesartan), Renin Inhibitors (Telmisartan, Aliskiren, Moexipril)), By Application (Hypertension, Heart Failure, Diabetic Nephropathy, and Others), By End-Use Industry (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Region

RAS Inhibitors Market size was valued at US$ XX billion in 2022 and is poised to grow at a significant CAGR of XX% from 2023-2029. RAS inhibitors are drugs that target components of the renin-angiotensin system to regulate blood pressure and fluid balance. ACE inhibitors block the action of ACE enzymes, reducing the production of angiotensin II, a vasoconstrictor that raises blood pressure. Common ACE inhibitors include lisinopril, enalapril, and captopril. These drugs play a crucial role in managing cardiovascular drugs and renal conditions associated with high blood pressure and heart failure. However, it's important to note that RAS inhibitors can have side effects such as hypotension, cough, and hyperkalemia. Therefore, their use should be monitored and guided by healthcare professionals. The global RAS inhibitors market is driven by the increasing prevalence of cardiovascular diseases (CVDs), which are the leading cause of death worldwide. RAS-acting agents are commonly used to treat hypertension and heart failure, major risk factors for CVDs. Ongoing research exploring their potential use in other conditions, like kidney disease, also contributes to market growth. The availability of generic versions of these drugs is making treatment more affordable and accessible. However, the market faces competition from alternative treatments and potential side effects associated with RAS-acting agents. Overall, the market is driven by the need to address the growing burden of CVDs and improve patient outcomes.

RAS Inhibitors Market Key Developments:
In November 2021, Boehringer Ingelheim announced the launch of a new fixed-dose combination product containing telmisartan and amlodipine besylate for the treatment of hypertension. The product, called Twynsta Duo, is now available in the U.S.